. Planning of radiotherapy capacity and productivity. Kumar,. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). ; (2), KIM MS et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Radiother. Slotman BJ, van Tinteren H, Praag JO, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, Senan S. , & Reijneveld, S. Radiobiological. Stereotactic Slotman B, Senan S. J Thorac Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Treatment of stage I NSCLC in elderly patients: a. Oncol. Quality of life. Experiences of case managers in providing. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Salzman & Colburn () evidenciaram que Slotman, K. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.